Members of RARS were given a special invite to have lunch and chat with the RUSM Class of 2026, Fall White Coat Ceremony, keynote speaker, Dr Sonal Bhatia.
Sonal Bhatia is Chief Medical Officer for Rare Disease. Her focus on patient centricity and drive to engage key stakeholders externally motivates her to elevate the voice of medical. She is passionate about leading the organization to become the “trusted partner and demonstrated leader in the Rare Disease community” we aspire to be in our strategic plan.
Prior to this role, Sonal held the position of VP, North America Medical Affairs Lead for Rare Disease. In this capacity, she played a key part in the successful launch of Tafamidis, which is still ongoing worldwide for Rare Disease. She also has experience preparing the healthcare marketplace for innovative solutions driving the delivery of medicines to patients, which will be critical to our future gene therapy pipeline. Sonal previously served as Senior Medical Director & Team Lead, for Eliquis, bringing about a new era of Real-World Evidence generation for physicians.
Sonal is actively involved with non-profit organizations focused on reducing healthcare disparities, specifically, access to cardiovascular health, healthy living and being a catalyst for change in women’s health. She currently serves on the Board of Directors for the American Heart Association (AHA) and is on the Executive Leadership for AHA Go Red for Women. She is a speaker at various panels and conferences internationally, driving the future of Medical Affairs.
Sonal received her medical degree from Ross University School of Medicine and completed her residency in Internal Medicine at the Mount Sinai School of Medicine in New York. She holds a dual bachelor’s degree in Cell & Molecular Biology and Spanish Studies from University of Toronto, Canada and was bestowed the 2018 Rising Star Award by the Healthcare Businesswomen’s Association (HBA).